Fundraising Fox

Incyclix Bio

Durham, US · Founded 2020 · Delaware LLC · 3 known investors

incyclixbio.com ↗

Incyclix Bio is a clinical-stage biotech company developing cell cycle control therapies that target the aberrant cell proliferation driving cancers, with a lead CDK2 inhibitor (INX-315). It focuses on cyclin-dependent kinase inhibitors as targets across tumor types including ovarian, breast, and lung cancers.

BiotechHealthtechin /arc-therapeutics-llc@incyclixbio

Founders & leadership

NS
Norman SharplessMember of the Board of Managers.
FN
Fredric N. EshelmanExecutive Officer and member of the Board of Managers.
PR
Patrick RobertsExecutive Officer and member of the Board of Managers.
SS
Sid SubramonyMember of the Board of Managers.

Investors · 3

Cape Fear BioCapitalDurham
Eshelman Ventures, LLCWilmingtonvia Fred Eshelman · inferred
Hatteras Venture PartnersResearch Triangle · $500K – $4M

Reported raises · per SEC filings

Form D private placements
▶$11.2MraisedAug 2025 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Norman SharplessDirector
  • Fredric N. EshelmanExecutive Officer, Director
  • Patrick RobertsExecutive Officer, Director
Offering amount
$20M
Amount sold
$11.2M
First sale
Aug 2025
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15MraisedJul 2023 · 5 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Sid SubramonyDirector
  • Patrick RobertsExecutive Officer, Director
  • Fredric N. EshelmanExecutive Officer, Director
Offering amount
$30M
Amount sold
$15M
First sale
Feb 2022
Incorporated
Limited Liability Company, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.